HIV-infected individuals with the CCR delta32/CCR5 genotype have lower HIV RNA levels and higher CD4 cell counts in the early years of the infection than do patients with the wild type. Copenhagen AIDS Cohort Study Group

T L Katzenstein; J Eugen-Olsen; B Hofmann; T Benfield; C Pedersen; Anton Iversen; A M Sørensen; P Garred; Uffe Koppelhus; A Svejgaard; J Gerstoft

HIV-infected individuals with the CCR delta32/CCR5 genotype have lower HIV RNA levels and higher CD4 cell counts in the early years of the infection than do patients with the wild type. Copenhagen AIDS Cohort Study Group

T L Katzenstein, J Eugen-Olsen, B Hofmann, T Benfield, C Pedersen, Anton Iversen, A M Sørensen, P Garred, Uffe Koppelhus, A Svejgaard, J Gerstoft

Abstract

The relations among serum HIV RNA levels, CD4 cell counts, presence of the mutant CCR5-allele in heterozygous form, and clinical outcome was analyzed in 96 patients from the Copenhagen AIDS Cohort. In the early years of the infection, patients with the CCR5 delta32/CCR5 genotype had significantly lower HIV RNA levels (p = 0.005) and higher CD4 cell counts (p <0.005) than did patients homozygous for the normal allele. The long-term clinical benefit of being heterozygous is small and cannot solely explain the large interpatient variation in progression rates. The beneficial effect of being heterozygous seems to be mediated by events in the early stages of the HIV infection.

Originalsprog	Engelsk
Tidsskrift	J Acquir Immune Defic Syndr Hum Retrovirol
Vol/bind	16
Udgave nummer	1
Sider (fra-til)	10-4
Antal sider	5
Status	Udgivet - 1997

FN’s Verdensmål

Dette resultat bidrager til følgende verdensmål

Fingeraftryk

Dyk ned i forskningsemnerne om 'HIV-infected individuals with the CCR delta32/CCR5 genotype have lower HIV RNA levels and higher CD4 cell counts in the early years of the infection than do patients with the wild type. Copenhagen AIDS Cohort Study Group'. Sammen danner de et unikt fingeraftryk.

Citationsformater

Katzenstein, T. L., Eugen-Olsen, J., Hofmann, B., Benfield, T., Pedersen, C., Iversen, A., Sørensen, A. M., Garred, P., Koppelhus, U., Svejgaard, A., & Gerstoft, J. (1997). HIV-infected individuals with the CCR delta32/CCR5 genotype have lower HIV RNA levels and higher CD4 cell counts in the early years of the infection than do patients with the wild type. Copenhagen AIDS Cohort Study Group. J Acquir Immune Defic Syndr Hum Retrovirol, 16(1), 10-4.

HIV-infected individuals with the CCR delta32/CCR5 genotype have lower HIV RNA levels and higher CD4 cell counts in the early years of the infection than do patients with the wild type. Copenhagen AIDS Cohort Study Group. / Katzenstein, T L; Eugen-Olsen, J; Hofmann, B et al.

I: J Acquir Immune Defic Syndr Hum Retrovirol, Bind 16, Nr. 1, 1997, s. 10-4.

Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › peer review

Katzenstein, TL, Eugen-Olsen, J, Hofmann, B, Benfield, T, Pedersen, C, Iversen, A, Sørensen, AM, Garred, P, Koppelhus, U, Svejgaard, A & Gerstoft, J 1997, 'HIV-infected individuals with the CCR delta32/CCR5 genotype have lower HIV RNA levels and higher CD4 cell counts in the early years of the infection than do patients with the wild type. Copenhagen AIDS Cohort Study Group', J Acquir Immune Defic Syndr Hum Retrovirol, bind 16, nr. 1, s. 10-4.

@article{cbc0b6b215d54547a6ef38eacdcfaedf,

title = "HIV-infected individuals with the CCR delta32/CCR5 genotype have lower HIV RNA levels and higher CD4 cell counts in the early years of the infection than do patients with the wild type. Copenhagen AIDS Cohort Study Group",

abstract = "The relations among serum HIV RNA levels, CD4 cell counts, presence of the mutant CCR5-allele in heterozygous form, and clinical outcome was analyzed in 96 patients from the Copenhagen AIDS Cohort. In the early years of the infection, patients with the CCR5 delta32/CCR5 genotype had significantly lower HIV RNA levels (p = 0.005) and higher CD4 cell counts (p <0.005) than did patients homozygous for the normal allele. The long-term clinical benefit of being heterozygous is small and cannot solely explain the large interpatient variation in progression rates. The beneficial effect of being heterozygous seems to be mediated by events in the early stages of the HIV infection.",

author = "Katzenstein, {T L} and J Eugen-Olsen and B Hofmann and T Benfield and C Pedersen and Anton Iversen and S{\o}rensen, {A M} and P Garred and Uffe Koppelhus and A Svejgaard and J Gerstoft",

year = "1997",

language = "English",

volume = "16",

pages = "10--4",

journal = "J A I D S",

issn = "1525-4135",

publisher = "Lippincott Williams & Wilkins",

number = "1",

}

TY - JOUR

T1 - HIV-infected individuals with the CCR delta32/CCR5 genotype have lower HIV RNA levels and higher CD4 cell counts in the early years of the infection than do patients with the wild type. Copenhagen AIDS Cohort Study Group

AU - Katzenstein, T L

AU - Eugen-Olsen, J

AU - Hofmann, B

AU - Benfield, T

AU - Pedersen, C

AU - Iversen, Anton

AU - Sørensen, A M

AU - Garred, P

AU - Koppelhus, Uffe

AU - Svejgaard, A

AU - Gerstoft, J

PY - 1997

Y1 - 1997

N2 - The relations among serum HIV RNA levels, CD4 cell counts, presence of the mutant CCR5-allele in heterozygous form, and clinical outcome was analyzed in 96 patients from the Copenhagen AIDS Cohort. In the early years of the infection, patients with the CCR5 delta32/CCR5 genotype had significantly lower HIV RNA levels (p = 0.005) and higher CD4 cell counts (p <0.005) than did patients homozygous for the normal allele. The long-term clinical benefit of being heterozygous is small and cannot solely explain the large interpatient variation in progression rates. The beneficial effect of being heterozygous seems to be mediated by events in the early stages of the HIV infection.

AB - The relations among serum HIV RNA levels, CD4 cell counts, presence of the mutant CCR5-allele in heterozygous form, and clinical outcome was analyzed in 96 patients from the Copenhagen AIDS Cohort. In the early years of the infection, patients with the CCR5 delta32/CCR5 genotype had significantly lower HIV RNA levels (p = 0.005) and higher CD4 cell counts (p <0.005) than did patients homozygous for the normal allele. The long-term clinical benefit of being heterozygous is small and cannot solely explain the large interpatient variation in progression rates. The beneficial effect of being heterozygous seems to be mediated by events in the early stages of the HIV infection.

M3 - Journal article

SN - 1525-4135

VL - 16

SP - 10

EP - 14

JO - J A I D S

JF - J A I D S

IS - 1

ER -